Company intelligence / Profile preview

Medibiofarma

Pamplona* / Cordovilla*, Navarra, Spainmedibiofarma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Medibiofarma develops disease-modifying therapies for serious conditions with high unmet medical need, focusing on small molecule drugs targeting well‐validated biological pathways. The company aims to de-risk assets by advancing them through proof-of-concept clinical trials before licensing. Its pipeline includes programs for cancer and neurodegenerative disorders, though specific trial results are not publicly detailed.

Therapeutic areas: OtherOncologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

MBF-118

4 more assets in the full pipeline.

Request access →

Partnerships

CROs/universities/research centers

Beyond the preview

Go deeper on Medibiofarma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medibiofarma.

Explore the full profile